Detection of extended spectrum β-lactamases among urinary Escherichia coli and Klebsiella pneumoniae from two centres

Jamahiriya Medical Journal

Volumn 10, Issue 1, 2010, Pages 10-16

  Buzayan, Muna Mohamed ^a   Tobgi, Rajab Salem ^b   Taher, Ibrahim ^b  

^a Libyan National Centre of Infectious Disease Prevention and Control Branch of Benghazi   (Libyan Arab Jamahiriya)

^b UNIVERSITY OF BENGHAZI   (Libyan Arab Jamahiriya)

Author keywords

Antibiotic resistance; DDST; E. coli; ESBL producing; HIV negative outpatients; HIV positive patients; K. pneumoniae

Indexed keywords

AMIKACIN; AMPICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; NALIDIXIC ACID; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; ENZYME ASSAY; ESCHERICHIA COLI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KLEBSIELLA PNEUMONIAE; NONHUMAN; URINARY TRACT INFECTION;

EID: 77953371458     PISSN: 20791216     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Cli Infect Dis 1997; 24(Suppl 1): S19-45.
2. Buch K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Cli Infect Dis 2001;32(7):1085-1089
3. 3- Knothe H, Shah P, Krcmery V, Antal M and Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae amd Serratia marcescens. Infection 1983;11(6):315-317 (Pubitemid 14213754)
4. Lazarova G, Rachkova K, Rukanova D, Djeneva H and Dukova I.Extended-spectrum β-lactamases (ESBL) producing Enterobacteriaceae- challenge in the medicine practice. Trakia J Sci 2008;6(Suppl. 1): 60-3.
5. 5- Pitout JDD, Nordmann P, Laupland KB and Poirel L. Emergence of Enterobacteriaceae Producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrobi Chemother 2005;56(1):52-59 (Pubitemid 41418336)
6. 6- Mugnier P, Casin I, Bouthors AT and Collatz E. Novel OXA-10-Derived Extended-Spectrum β-Lactamases Selected In Vivo or In Vitro. Antimicrobi Agents Chemother 1998; 42(12): 3113-3116 (Pubitemid 28553727)
7. 7- Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemiology of ciprofloxacin resistance and its relationship to extended- spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30(3): 473-478 (Pubitemid 30205291)
8. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2001;6(issue 9):460-463
9. 9- Wang M, Sahm DF, Jacoby GA and Hooper DC. Emerging plasmid-mediated quinolones resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004; 48(4): 1295-1299 (Pubitemid 38405484)
10. 10- Mammeri H, Van De Loo M, Poirel L, Martinez LM and Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob. Agents Chemother 2005;49(1):71-76 (Pubitemid 40065774)
11. 11- Briggs S, Ussher J and Taylor S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital. Journal of the New Zealand Medical Association 2005; 118(1218). (Pubitemid 41522310)
12. Al-Jasser AM. Extended-Spectrum Beta-Lactamases (ESBLs): A Global Problem. Kuwait Med J 2006; 38(3): 171-185
13. Jarlier V, Nicolas MH, Fournier G and Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer ?-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10:867-878
14. Sanders CC, Barry AL, Washington JA et al. Detection of extended-spectrum beta- lactamases-producing members of the family Enterobacteriaceae with Vitek ESBL test. J Clin Microbiol 1996;34(12):2997-3001.
15. Ho PL,Chow KH, Yuen KY, Ng WS and Chau PY. Comparison of a novel, inhibitor- potentiated disc-diffusion test with other methods for the detection of extended-spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother1998;42: 49-54.
16. Cagatay AA, Kocagoz T and Eraksoy H. Diosensimedia: a novel culture medium for rapid detection of extended spectrum β-lactamases. BMC Infectious Diseases 2003; 3(22): 1-6.
17. 17- Stürenburg E, Lang M, Horstkotte MA, Laufs R and Mack D. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum β-lactamases in clinical Isolates of oxyimino- cephalosporin-resistant Gram-negative bacteria. J Antimicrob Chemother 2004; 54(5): 870-875 (Pubitemid 39529980)
18. Vespero EC, Perugini MRE and Saridakis HO. Screeninig and confirmatory assays for detection of ESBLs (extended- spectrum β-lactamases) production by Klebsiella pneumoniae isolates. Semina:Ciências Biológicas e da Saúde, Londrina 2007; 28(1): 33-38
19. El Astal ZY and Ramadan H. Occurrence of Extended-Spectrum Beta-Lactamases in Isolates of Klebsiella pneumoniae and Escherichia coli. International Journal of Integrative Biology 2008; 2(2): 122-128
20. Clinical and Laboratory standards Institute(CLSI) . Performance Standards for Antimicrobial Susceptibility testing; fifteenth Informational Supplement M100-S15. CLSI, Wayne,PA,USA 2005;25(1).
21. 21- Schooneveldt J.M, Nimmo GR and Giffard P. Detection and characterization of extended spectrum beta-lactamases in Klebsiella pneumoniae causing Nosocomial infection. Pathology 1998;30(2):164-168 (Pubitemid 28211788)
22. Wagenlehner FME and Naber KG. Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections. Int J Antimicrob Agents 2004;23Suppl 1:S24-9.
23. Levy SB, FitzGerald GB and Macone AB. changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. N Engl J Med 1976;295:583-588
24. Kiffer CR, Mendes C, Oplustil CP and Sampaio JL. Antibiotic resistance and Trend of urinary pathogens in general outpatients from a major Urban city. International Braz J Urol 2007;33(1):42-49
25. Stratchounski L, Shevelev A, Korovina N et al. Resistance of E.coli isolated from children with community-acquired urinary tract infections in Russia: Results of multicenter study "ARMID". 42ed Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2002; 28-30 September, San Diego, USA.
26. Bean DC, Krahe D and Wareham DW. Antimicrobial resistance in community and Nosocomial Escherichia coli urinary tract isolates, London 2005-2006.Ann Clin Microbiol Antimicrob 2008; 7:13.
27. Al-Tawfiq JA. Increasing antibiotic resistance among isolates of Escherichia coli recovered from inpatients and outpatients in a Saudi Arabian Hospital. Infect Control Hosp Epidemiol 2006; 27(7):748-753
28. Dash N, Al-Zarouni M, Al-Kous N et al. Distribution and Resistance Trends of Community Associated Urinary Tract Pathogens in Sharjah, UAE. Microbiology Insights 2008; 1: 41-45.
29. 29- Dromigny JA, Nabeth P, Juergens-Behr A and Perrier-Gros-Claude D. Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal. Journal of Antimicrobial chemotherapy 2007;56(1):236-239. (Pubitemid 41418365)
30. Mashouf RY, Babalhavaeji H and Yousef J. Urinary Tract Infections: Bacteriology and Antibiotic Resistance Patterns. Indian Pediatr 2009;46:617-620.
31. Shah AA ,Hasan F, Ahmed S and Abdul Hameed. Prevalence of extended-spectrum β-Lactamases in Nosocomial and outpatients (ambulatory). Pak J Med Sci 2003; 19(3): 187-191
32. 32- Kader AA and Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med 2005;25(3):239-242. (Pubitemid 40959776)
33. Heffernan H and Woodhouse R. Prevalence of extended-spectrum ß-lactamase among urinary Escherichia coli and Klebsiella in New Zealand in 2006. Communicable Disease Group ESR Porirua. November 2006.
34. Bouchillon SK, Johnson BM, Hoban DJ et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004;24(2):119-24.
35. Hirakata Y, Matsuda J, Miyazaki Y et al. Regional variation in the prevalence of extended spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005; 52(4):323-9.
36. Fam.NS and El-Damarawy MM. CTX-M-15 Extended Spectrum Beta-Lactamases detected from Intensive Care Unit of an Egyptian Medical Research Institute. Res J Medic and Med Sci 2008; 3(1): 84-91.
37. 37- Babypadmini S and Appalaraju B. Extended spectrum-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004:22(issue:3):172-174 (Pubitemid 39206740)
38. Coque TM., Baquero F. and Canton R. Review articles Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe 2008; 13 Issue 47. www.eurosurveillance. org.